← All trials
NCT06943495
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 15, 2025
- Primary completion
- Mar 31, 2029
- Completion date
- Mar 31, 2033
- First posted
- Apr 24, 2025
- Last posted
- Sep 9, 2025
- Enrollment
- 60
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Laval UniversityLead sponsor
- NovartisCollaborator
- Laval UniversityCollaborator
- Laval UniversityOfficial
- Canadian Institutes of Health Research (CIHR)Collaborator
- Laval UniversitySponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.